Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
Clinical trial NCT06779539 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06779539
- Sponsor
- West China Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-15
- Primary completion
- 2028-06-12
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.